IonQ (NYSE:IONQ) announced results of a collaborative research program between the company, AstraZeneca (NASDAQ:AZN), Amazon Web Services (NASDAQ:AMZN) and Nvidia (NASDAQ:NVDA) to develop and show a quantum-accelerated computational chemistry workflow.
The IonQ-designed workflow provides an example of a hybrid quantum-classical workflow that helps provide solutions to complex pharmaceutical development challenges, and has the potential to improve speed and efficiency in the drug development process, according to the company.
The demonstration focused on a critical step in a Suzuki-Miyaura reaction — a class of chemical transformations used for the synthesis of small molecule drugs. By integrating IonQ’s Forte quantum processing unit, or QPU, with the Nvidia CUDA-Q platform through Amazon Braket (accelerated with NVIDIA H200 GPUs) and AWS ParallelCluster services, the team achieved more than 20 times improvement in end-to-end time-to-solution compared to previous benchmarks.
IonQ noted that the technique maintained accuracy while reducing the overall expected runtime from months to days.
“By combining quantum computers on Amazon Braket with scalable GPU resources on AWS, we’re supporting AstraZeneca to envision how future quantum computers will be used to accelerate research in computational chemistry,” said Eric Kessler, GM of Amazon Braket at AWS.
IonQ said that the results show how hybrid quantum computing can overcome computational limits in high-accuracy molecular modeling and enables the analysis of more complex chemical systems.
More on IonQ, AstraZeneca and Nvidia
- Nvidia: After A 50% Run, Near-Term AI Spending Outlook Remains Uncertain (Rating Downgrade)
- AstraZeneca: Fascinating Company With Lofty Ambitions – Just Not A Buy Yet
- Nvidia: I Predicted $150 By Year End – I Was Dead Wrong
- Nvidia, UK financial regulator team up for AI sandbox; Huang to join British Prime Minister at tech week
- Biggest stock movers Monday: Air mobility stocks, and more